Key result
Changes in nocturnal systolic blood pressure over 12 weeks of therapy were significantly associated with changes in circulating platelet-derived extracellular vesicle levels (adjusted R2=0.23; P=0.01).
Why the study?
Elevated nocturnal BP is associated with cardiovascular risk, and circulating EVs correlate with BP, but whether BP reduction is paralleled by EV changes was unknown.
Does blood pressure lowering therapy reduce circulating platelet-derived extracellular vesicles in hypertensive patients?
Observational (n=55)
Does blood pressure lowering therapy reduce circulating platelet-derived extracellular vesicles in hypertensive patients?
Circulating platelet-derived extracellular vesicles correlate with therapy-induced reductions in nocturnal blood pressure, suggesting they may serve as a biomarker for BP changes.
Answers are grounded in this paper and cite their sources.
Supports platelet-derived EVs tracking nocturnal BP response in hypertension; leaves open biomarker utility pending randomized trials.
INTRODUCTION: Elevated nocturnal blood pressure (BP) is closely associated with increased risk of cardiovascular (CV) events. Circulating extracellular vesicles (EVs) have been proposed as a potential CV risk biomarker and shown to correlate with BP. The present study aimed to assess whether a reduction in BP is paralleled by respective changes in EVs. METHODS: Fifty-five hypertensive patients (age: 57.7 ± 14.1 years) were included in the study. EVs and BP were assessed at baseline and at 12 weeks follow-up. Interventions to lower BP included advice on life-style modification only or life-style advice combined with additional pharmacotherapy. EVs were evaluated by flow cytometry (CD41+/Annexin V+) and BP by unobserved automated office BP and ambulatory BP monitoring. RESULTS: Nocturnal systolic BP correlated with EV levels at baseline ( P = 0.01). Multivariable regression models showed that changes in nocturnal systolic BP (adjusted R2 = 0.23; P = 0.01) and diastolic BP (adjusted R2 = 0.18; P = 0.02) were associated with respective changes in EV levels. Furthermore, intervention-induced improvement of systolic dipping was associated with a reduction in EVs in the univariate analysis (adjusted R2 = 0.06; P = 0.03). In contrast, systolic office, 24 h- and daytime-BP did not show significant associations with EVs. Patients whose medication was up-titrated at baseline showed a trend towards lower EV levels at follow-up (absolute change of -1.7 ± 1.3 EV/μl; P = 0.057). CONCLUSIONS: Circulating platelet-derived EVs were positively associated with nocturnal BP and therapy-induced changes over a 12-week treatment period. EVs may provide an integrated measure of BP changes achieved with pharmacotherapy.
No takes yet. Share an insight, caveat, or question.
Lugo‐Gavidia et al. (2022) conducted an observational in Hypertension (n=55). Blood pressure lowering therapy (lifestyle modification and/or pharmacotherapy) was evaluated on Association between changes in nocturnal systolic blood pressure and changes in extracellular vesicle levels (adjusted R2 0.23, p=0.01). Changes in nocturnal systolic blood pressure over 12 weeks of therapy were significantly associated with changes in circulating platelet-derived extracellular vesicle levels (adjusted R2=0.23; P=0.01).
Synapse has enriched 10 related papers. Consider them for comparative context: